Company news

Precipio, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Precipio Launches Its Much-Anticipated Quantitative BCR-ABL 2.0 Panel

August 7, 2023

Precipio’s Operational Efficiency Measures Continue To Reduce Cash Burn And Move The Company Towards Breakeven

August 2, 2023

Precipio Unaudited Q2-2023 Revenues Show combined increase of 25% over Q1-2023

July 31, 2023

Precipio’s Omnia™ Methodology Enables Diagnosis of MDS With Peripheral Blood Instead of Bone Marrow Biopsy

June 13, 2023

Precipio Enters into Collaboration with Prestigious New York-based Institution to Develop Revolutionary Brain Tumor Panel using HemeScreen® Technology

June 12, 2023

Precipio, Inc. Announces Pricing of $2 Million Registered Direct Offering and Concurrent Private Placement

June 7, 2023

Projected cash burn reduced by $1.5 million annually from Three Operational Efficiency Projects

June 6, 2023

Precipio’s Lab Detects BCR-ABL1 Oncogene Co-Expression of p190 & p210 Isoforms in a CML Patient By Using HemeScreen® Technology

May 21, 2023

Precipio Shares Growth Catalysts For HemeScreen

May 16, 2023

Precipio Announces Q1-2023 Shareholder Update Call

May 14, 2023

Precipio Signs Another HemeScreen™ Customer

May 3, 2023

Precipio Adds Substantial Pathology Customer to its Diagnostic Services Division

May 3, 2023

Precipio Granted 180-day Extension From NASDAQ To Regain Compliance

April 26, 2023

Precipio Unaudited Q1-2023 Product Revenues Exceed The Two Prior Quarters (Q3+Q4 of 2022) Combined

April 18, 2023

Precipio Announces 2022 Fourth Quarter and Year-End Shareholder Update Call

March 27, 2023

Precipio Ships First IV-Cell® Order to Major US Healthcare System

March 20, 2023

Precipio continues to sign up and onboard HemeScreen™ customers

March 6, 2023

ThermoFisher Salesforce Votes Precipio’s HemeScreen® as “Best New Product”

February 13, 2023

Precipio Signs Another Major HemeScreen™ Customer

January 10, 2023

Precipio Signs Additional Major HemeScreen™ Customer

December 5, 2022

Precipio Presents Poster on HemeScreen® Study at Association of Molecular Pathology (AMP) 2022 Annual Conference

November 6, 2022

Precipio Announces Third Quarter Shareholder Update Call

November 1, 2022

Precipio Signs Agreement with Another Major US Healthcare Distributor for HemeScreen™

September 14, 2022

Sharon Robins Joins Precipio’s Products Division as Senior Director of Laboratory & Hospital Sales

August 23, 2022

Precipio Launches New 1-Step Technology for all HemeScreen Assays

August 15, 2022

Toni-Ann Mills Joins Precipio’s Products Division to Lead Channel Partner Training, Learning & Development

August 9, 2022

Precipio Announces Second Quarter Shareholder Update Call

August 7, 2022

Precipio to distribute HemeScreen® through Fisher Healthcare channel

July 19, 2022

Precipio requests that all Stockholders that have not yet voted, proceed to cast their vote

June 13, 2022

Keith Meadors Joins Precipio to Lead its Products Division

June 12, 2022

Precipio Receives CE-IVD Certification to Market Multiple HemeScreen® Panels in Europe

May 23, 2022

Precipio Signs First IV-Cell Customer Agreement

May 9, 2022

Precipio customer American Oncology Network (AON) selected to present HemeScreen® technology case study at Industry leading clinical laboratory conference

April 25, 2022

Precipio Announces 2021 Fourth Quarter and Year-End Shareholder Update Call

March 21, 2022

Precipio Inc. Announces the Resignation of its Chief Financial Officer and Appointment of Interim CFO

March 20, 2022

Precipio Releases Year-End 2021 Preliminary Unaudited Results and Outlook for 2022

February 23, 2022

New York State Approves Precipio’s HemeScreen for POL clinical use

November 17, 2021

Precipio Announces Q3-2021 and year-end Shareholder Update Call

October 31, 2021

American Oncology Network Partners with Precipio to Bring HemeScreen® into AON’s Laboratory

August 25, 2021

Precipio Reschedules Q2-2021 Shareholder Update Call

August 19, 2021

Precipio Corrects Announcement of Q2-2021 Shareholder Update Call

August 12, 2021

Precipio Announces Q2-2021 and year-end Shareholder Update Call

August 11, 2021

Precipio Announces Preliminary Unaudited Q2-2021 Revenues of $2.3M

July 27, 2021

Precipio Terminates its Equity Line

June 14, 2021

Precipio Launches HemeScreen® Anemia Panel, a One-of-its-Kind Testing Tool

June 7, 2021

Precipio Announces Q1-2021 and year-end Shareholder Update Call

May 13, 2021

Precipio Launches New HemeScreen Panel for AML, with an unparalleled 4-hour turnaround-time

May 9, 2021

Precipio Launches its Rapid COVID-19 Antibody test on Amazon Platform

May 2, 2021

Current Signed Customers Expected to Generate $1M Annualized Reported Revenues from Precipio’s HemeScreen POL Offering by Q4-2021

April 25, 2021

Precipio Enters Into an At-The -Market (ATM) Financing Arrangement

April 4, 2021

← Newer news releases · Older news releases →

Calls

The 5 newest of 9 calls. Every call is listed under its year.

Decks